WO2023114296A3 - Préparations de vésicules extracellulaires - Google Patents

Préparations de vésicules extracellulaires Download PDF

Info

Publication number
WO2023114296A3
WO2023114296A3 PCT/US2022/052841 US2022052841W WO2023114296A3 WO 2023114296 A3 WO2023114296 A3 WO 2023114296A3 US 2022052841 W US2022052841 W US 2022052841W WO 2023114296 A3 WO2023114296 A3 WO 2023114296A3
Authority
WO
WIPO (PCT)
Prior art keywords
extracellular vesicle
vesicle preparations
preparations
extracellular
evs
Prior art date
Application number
PCT/US2022/052841
Other languages
English (en)
Other versions
WO2023114296A2 (fr
Inventor
Derek DORMAN
Laura Jackson
Francesco MARIA DEL RE
Collin MCKENNA
Maria Sizova
Bill Wang
Alicia BALLOK
Original Assignee
Evelo Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences, Inc. filed Critical Evelo Biosciences, Inc.
Publication of WO2023114296A2 publication Critical patent/WO2023114296A2/fr
Publication of WO2023114296A3 publication Critical patent/WO2023114296A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/06—Investigating concentration of particle suspensions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/06—Investigating concentration of particle suspensions
    • G01N15/075—Investigating concentration of particle suspensions by optical means

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des solutions et des formes séchées de vésicules extracellulaires (EV) qui sont utiles en tant qu'agents thérapeutiques, ainsi que des compositions thérapeutiques associées.
PCT/US2022/052841 2021-12-14 2022-12-14 Préparations de vésicules extracellulaires WO2023114296A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163289406P 2021-12-14 2021-12-14
US63/289,406 2021-12-14
US202263324322P 2022-03-28 2022-03-28
US63/324,322 2022-03-28
US202263333654P 2022-04-22 2022-04-22
US63/333,654 2022-04-22

Publications (2)

Publication Number Publication Date
WO2023114296A2 WO2023114296A2 (fr) 2023-06-22
WO2023114296A3 true WO2023114296A3 (fr) 2023-08-10

Family

ID=85150820

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2022/052841 WO2023114296A2 (fr) 2021-12-14 2022-12-14 Préparations de vésicules extracellulaires
PCT/US2022/052838 WO2023114293A1 (fr) 2021-12-14 2022-12-14 Dosages de vésicules extracellulaires

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2022/052838 WO2023114293A1 (fr) 2021-12-14 2022-12-14 Dosages de vésicules extracellulaires

Country Status (1)

Country Link
WO (2) WO2023114296A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024102226A1 (fr) 2022-10-14 2024-05-16 Evelo Biosciences, Inc. Procédés de dosage de substances médicamenteuses et de produits médicamenteux à l'aide de lignées cellulaires comportant des gènes rapporteurs inductibles par nf-kb

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019182372A1 (fr) * 2018-03-21 2019-09-26 ㈜로제타엑소좀 Vésicules extracellulaires bactériennes ayant une toxicité réduite, et leur utilisation
US20200254028A1 (en) * 2017-09-08 2020-08-13 Evelo Biosciences, Inc. Bacterial extracellular vesicles
WO2020252149A1 (fr) * 2019-06-11 2020-12-17 Evelo Biosciences, Inc. Vésicules extracellulaires microbiennes traitées

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US5292522A (en) 1989-06-20 1994-03-08 Rohm Gmbh Aqueous film coating agent for solid medicaments
US5047258A (en) 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19631084A1 (de) 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
EP1101490B1 (fr) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable de liberer un medicament au niveau d'un site cible dans l'intestin
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
DE10260919A1 (de) 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen und Nahrungsergänzungsmitteln mit Konzentrationsgradienten im Überzug
CA2543172A1 (fr) 2003-10-31 2005-05-19 Dexcel Ltd. Formulation stable contenant du lansoprazole
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
EP2961387B1 (fr) 2013-03-01 2017-08-23 BPSI Holdings, LLC. Pelliculages à libération retardée contenant du silicate de calcium et substrats revêtus avec celui-ci
HRP20220747T1 (hr) 2017-06-14 2022-10-14 4D Pharma Research Limited Pripravci koji sadrže bakterijske sojeve
CN108169199B (zh) * 2018-02-09 2020-07-24 大连理工大学 一种利用荧光比率进行外泌体快速定量的方法
JP7397071B2 (ja) 2018-06-07 2023-12-12 アルチュジェン セラピューティクス リミテッド Ｃ．ディフィシル治療方法及び組成物
EP3893905A1 (fr) 2018-12-12 2021-10-20 4D Pharma Research Limited Compositions comprenant des souches bactériennes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200254028A1 (en) * 2017-09-08 2020-08-13 Evelo Biosciences, Inc. Bacterial extracellular vesicles
WO2019182372A1 (fr) * 2018-03-21 2019-09-26 ㈜로제타엑소좀 Vésicules extracellulaires bactériennes ayant une toxicité réduite, et leur utilisation
WO2020252149A1 (fr) * 2019-06-11 2020-12-17 Evelo Biosciences, Inc. Vésicules extracellulaires microbiennes traitées

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BARI ET AL: "Adipose Mesenchymal Extracellular Vesicles as Alpha-1-Antitrypsin Physiological Delivery Systems for Lung Regeneration", CELLS, vol. 8, no. 9, 23 August 2019 (2019-08-23), pages 965, XP055786126, DOI: 10.3390/cells8090965 *

Also Published As

Publication number Publication date
WO2023114296A2 (fr) 2023-06-22
WO2023114293A1 (fr) 2023-06-22

Similar Documents

Publication Publication Date Title
MX2021010160A (es) Preparaciones de membrana bacteriana.
MX2021015427A (es) Vesiculas extracelulares microbianas procesadas.
MX2020002660A (es) Vesiculas extracelulares de prevotella.
WO2018154145A3 (fr) Composés pour le traitement de la peau
MX2020002659A (es) Vesiculas extracelulares bacterianas.
WO2023114296A3 (fr) Préparations de vésicules extracellulaires
MY195500A (en) Vesicles Derived From Lactobacillus Paracasei And Use Of Same
MX2022003570A (es) Composiciones de vesícula extracelular.
DK1296647T3 (da) Polymermicellepræparater
NO20065726L (no) Forbindelser og sammensetninger for avlevering av aktive forbindelser.
TWD201836S (zh) 通訊耳機之部分
TW200605863A (en) Bazedoxifene acetate formulations
DE502007002815D1 (de) Polihexanidhaltige Liposomen
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CR20230100A (es) Compuestos fosfolípidos y usos de los mismos
WO2006029074A3 (fr) Methodes de traitement et de prevention transmembranaires de l'otite moyenne
MY162687A (en) Methods and compositions for rapid treatment of otitis externa
YU70201A (sh) Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobadjanje farmakološki aktivnih jedinjenja
MX2021012708A (es) Formulaciones novedosas que comprenden melflufen.
TWD206074S (zh) 美容按摩滾輪
WO2023081762A3 (fr) Recombinases à sérine
GEP20227384B (en) Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment
WO2021054927A3 (fr) Dérivés du glutathion-cholestérol en tant qu'agents ciblant le cerveau
MX2023010406A (es) Biopolimeros para uso topico.
TR200102778T2 (tr) Lipozom preparatları

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22851408

Country of ref document: EP

Kind code of ref document: A2